Managing DME When Anti-VEGF Response Is Limited - Top_Thought_Leaders - MDSpire

Managing DME When Anti-VEGF Response Is Limited

Retina Minute: Drs. Kuppermann and Singer discuss week-12 findings from the ERLYDEX trial in anti-VEGF suboptimal responders

  • By

  • Baruch D. Kuppermann, MD, PhD

  • Michael A. Singer, MD

  • March 1, 2026

  • 5 min

Share

Top Thought Leaders in Ophthalmology

Brief introduction explaining scope and methodology.

Original Source(s)

Managing DME When Anti-VEGF Response Is Limited

  • by Baruch D. Kuppermann, MD, PhD, Michael A. Singer, MD

  • March 1, 2026

Related Content

Lutein Supplementation May Improve Outcomes in Early AMD

Meta-analysis found statistically significant improvements, with clearest benefits in early-stage disease

Comparative Analysis of Structural and Microvascular Alterations in Anisometropic Amblyopia Using Swept-Source OCTA

Could Red-Light Therapy Change Myopia Care? 

Across 28 trials, pediatric patients receiving therapy had less myopia progression over 12 months, though long-term risks remain under study.